Emergo Therapeutics

Emergo Therapeutics is a private, pre-revenue biotech developing immune-modulating small molecules for conditions characterized by hyperactive cytokine release, such as cytokine storms. The company's core technology focuses on curtailing cytokine release from mast cells, with its lead asset, Norketotifen, in development for long COVID and influenza-like illnesses—two areas with significant unmet need. Founded in 2016, Emergo is positioned in the large and growing market for immunology and respiratory therapeutics, though it faces risks common to early-stage drug development, including clinical trial execution and competition.

Small molecule platform focused on modulating the immune system by curtailing the release of inflammation-inducing cytokines from mast cells and other immune cells, aiming to restore balance without causing immunosuppression.

The long COVID treatment landscape is nascent but rapidly evolving, with numerous biopharma companies exploring immunomodulators, antivirals, and other approaches. In influenza, Emergo would compete against established antivirals (e.g., Tamiflu, Xofluza) and symptomatic treatments. Its proposed mechanism of immune modulation without suppression is a key differentiator.